Tetra Bio-Pharma Inc. Receives Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product
February 01 | 2017
PhytoPain Pharma, a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its planned clinical trial for PhytoPain Topical Gel Relief (“PPTGR”), being developed as a locally administered therapeutic for the treatment of Chemotherapy-Induced Neuropathic Pain (“CIPN”).
CIPN is a common adverse effect of cancer therapy and a frequent reason why cancer patients stop their treatment early. For some patients, the severity of the symptoms can be reduced by lowering the dose of chemotherapy or temporarily stopping it. In other patients the symptoms of CIPN may last for months or years after the cancer therapy has stopped. CIPN symptoms are managed using the same analgesics used to manage other types of neuropathic pain. Some of these analgesics also cause intolerable side effects in patients. The use of a topical counterirritant may help reduce the symptoms of CIPN and avoid exposing some patients to oral neuropathic pain analgesics.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
CIPN is a common adverse effect of cancer therapy and a frequent reason why cancer patients stop their treatment early. For some patients, the severity of the symptoms can be reduced by lowering the dose of chemotherapy or temporarily stopping it. In other patients the symptoms of CIPN may last for months or years after the cancer therapy has stopped. CIPN symptoms are managed using the same analgesics used to manage other types of neuropathic pain. Some of these analgesics also cause intolerable side effects in patients. The use of a topical counterirritant may help reduce the symptoms of CIPN and avoid exposing some patients to oral neuropathic pain analgesics.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
Phone: (514) 220-9225
Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
Phone: (343) 689-0714
Dr. Guy Chamberland
Chief Science Officer
Phone: (514) 220-9225
Tetra Bio-Pharma Inc.
André Rancourt
Chief Executive Officer
Phone: (343) 689-0714
Find out what experts say about profiting from the cannabis market in 2021!
Read our FREE 2021 cannabis outlook report!
CanBud Distribution Corporation Closes 2M Second and Final Tranche of its Oversubscribed Private Placement Offering
March 09 | 2021
CanBud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“CanBud” or the “Corporation”) is pleased to announce that it has closed the final tranche of its oversubscribed non-brokered private placement for aggregate gross proceeds of approximately $4,730,000 (the “Offering”).
The Corporation issued a combined total of 39,409,346 units (each a “Unit“) at price of $0.12 per Unit, with each Unit comprised of one common share in the capital of the Corporation (each a “Common Share“) and one common share purchase warrant (each a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.22 within 24 months of the closing of the Offering (the “Warrant Term“), provided, however that if the closing price of the Common Shares on the Canadian Securities Exchange (the “CSE“) (or any such other stock exchange in Canada as the Common Shares may trade at the applicable time) is $0.25 or greater per Common Share for a period of five (5) consecutive trading days at any time after the closing date of the Offering, the Corporation may accelerate the Warrant Term such that the Warrants shall expire on the date which is 30 days following the date a press release is issued by the Corporation announcing the reduced warrant terms.
<p>Under the final tranche of the Offering, finder’s fees in the aggregate amount of $68,690.97 in cash and 572,425 broker warrants (the “<b>Broker Warrants</b>“) were paid to a syndicate of arm’s-length finders, with the exception of $33,831.00 <b> </b>and 281,925<b> </b>Broker Warrants paid to Florence Wealth Management Inc. (“<b>Florence</b>“). Raj Ravindran, CFO and Director of the Corporation, is the ultimate designated person and CEO of Florence. The Broker Warrants were issued on the same terms as the Warrants. In total, $151,481.36 in finders fees and 1,262,345 Broker warrants were paid to registered finders pursuant to the Offering. </p>
<p>The proceeds raised from the Offering will be used by the Corporation for working capital, business development and general corporate purposes.</p>
<p>Two directors of the Corporation (the “<b>Related Parties</b>“) participated in the Offering. The Offering constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 – <i>Protection of Minority Security Holders in Special Transactions</i> (“<b>MI 61-101</b>“). The Offering is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of securities being issued to the Related Parties nor the consideration being paid by the Related Parties exceeded 25% of the Corporation’s market capitalization. A material change report in respect of this related party transaction will be filed by the Corporation but could not be filed at least 21 days prior to the closing of the Offering as the details of the Offering, and the confirmation of insider participation in the Offering, was not definitively known to the Corporation until the date of the closing of the Offering and the board of directors determined that it was in the best interests of the Corporation to close the Offering as soon as practicable.</p>
<p>All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after closing. Completion of the Offering is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals, including approval of the CSE.</p>
<p>None of the securities issued in the Offering will be registered under the United States Securities Act of 1933, as amended (the “<b>1933 Act</b>“), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful. All securities issued pursuant to the Offering will be subject to a statutory hold period expiring four months and one day after closing of the Offering. </p>
<p>The Corporation also issued 476,190 Common Shares at a deemed share price of $0.21 per Common Share to a consultant of the Corporation. The Common Shares were issued further to the Corporation’s press releases dated January 7, 2021 and January 18, 2021. The Common Shares will be subject to a statutory hold period expiring on the date that is four months and one day from the date of issuance.</p>
<p><b>About Canbud Distribution Corporation</b></p>
<p>Canbud Distribution Corporation is a science and technology health and wellness company that encompasses plant based, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) verticals. <br/><a href="https://investingnews.com/company-profiles/canbud-distribution" rel="noopener noreferrer" target="_blank">www.canbudcorp.com</a><br/><a href="https://www.newsfilecorp.com/redirect/80yriyomn" rel="noopener noreferrer" target="_blank">https://www.instagram.com/empathyplantco/?hl=en</a></p>
<p>For further information, please contact:<br/><a href="mailto:ir@canbudcorp.com" rel="noopener noreferrer" target="_blank">ir@canbudcorp.com</a><br/>or<br/>Robert Tjandra, President and COO<br/>Tel: 1 416 847 7312</p>
<p><i><b>Notice Regarding Forward-Looking Information</b></i></p>
<p><i>This news release is not an offer to sell, or a solicitation of an offer to buy or sell, any securities of the Corporation and may not be relied upon in connection with the purchase or sale of any such security.</i></p>
<p><i>This news release contains “forward-looking information” within the meaning of Canadian securities legislation. The forward-looking information contained in this news release represents the expectations of the Corporation as of the date of this news release and, accordingly, is subject to change after such date. Forward-looking information includes information including statements with respect to the future exploration performance of the Corporation. Forward-looking information is based on, among other things, opinions, assumptions, estimates and analyses that, while considered reasonable by the Corporation at the date the forward-looking information is provided, are inherently subject to significant risks, uncertainties, contingencies and other factors that may cause actual results and events to be materially different from those expressed or implied by the forward-looking information. The risks, uncertainties, contingencies and other factors that may cause actual results to differ materially from those expressed or implied by the forward-looking information may include, but are not limited to (i) adverse market conditions; (ii) risks inherent in the CBD, psychedelics and vegan protein industries in general; (iii) the inability of the Corporation to complete the Offering and close the Offering; (iv) the CSE not approving the Offering; (v) the use of the proceeds from the Offering, or (v) risks generally associated with the Corporation’s business, as described in the Corporation’s public filings on SEDAR, which readers are encouraged to review in detail prior to any transaction involving the securities of the Corporation. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Corporation does not intend to update these forward-looking statements. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date.</i></p>
<p><i><b>NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES</b><br/></i></p>
<p id="corporateNewsLogoContainer"><img alt="Corporate Logo" class="lazy" data-src="https://orders.newsfilecorp.com/files/7448/76489_4b516c77c4f0db5f_logo.jpg" data-srcset="" id="corporateNewsLogo" src="https://orders.newsfilecorp.com/files/7448/76489_4b516c77c4f0db5f_logo.jpg" srcset=""/></p>
<p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://www.newsfilecorp.com/redirect/yQJgikVyk" rel="noopener noreferrer" target="_blank">https://www.newsfilecorp.com/release/76489</a></p>
<p><img alt="" class="lazy" data-src="https://www.newsfilecorp.com/newsinfo/76489/310" data-srcset="" src="https://www.newsfilecorp.com/newsinfo/76489/310" srcset=""/></p>
</div>
<p>News Provided by Newsfile via QuoteMedia</p>
<p></p>
Keep reading...
Show less
Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands) announces that the letter of intent with Franchise Cannabis Corp. (“FCC”), previously announced in January, has been terminated. The previously announced European joint venture with FCC will continue and allow the Company to launch and tailor its products to European consumer demands
In connection with termination of the merger transaction with FCC, the Company has agreed to pay FCC $100,000 in cash and to issue FCC 5,000,000 common shares of the Company at a deemed value of $0.05 per share. The common shares will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.
<p>Following termination of the transaction, the Company intends to apply to the Canadian Securities Exchange for the reinstatement of trading in its common shares under the existing ticker symbol “TBI”.</p>
<p><strong>About <a href="https://investingnews.com/company-profiles/thoughtful-brands-cse:tbi/">Thoughtful Brands Inc.</a> </strong><br/><a href="https://investingnews.com/company-profiles/thoughtful-brands-cse:tbi/">Thoughtful Brands Inc.</a> is an eCommerce direct-to-consumer CBD and natural health products company that researches, develops, markets and distributes products in North America.</p>
<p><strong>ON BEHALF OF THE BOARD OF DIRECTORS</strong><br/><a href="https://investingnews.com/company-profiles/thoughtful-brands-cse:tbi/">Thoughtful Brands Inc.</a><br/>Ryan Hoggan<br/>Chief Executive Officer</p>
<p>For further information, readers are encouraged to contact Joel Shacker, President at (604) 423-4733 or by email at <a href="mailto:info@thoughtful-brands.com" rel="noopener noreferrer" target="_blank">info@thoughtful-brands.com</a>.</p>
<p><em>Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.</em></p>
<p><strong>Cautionary Note Regarding Forward-Looking Statements:</strong><br/>All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to its plans to acquire additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its eCommerce technology platform. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.</p>
<p><strong>SOURCE: </strong><a href="https://investingnews.com/company-profiles/thoughtful-brands-cse:tbi/">Thoughtful Brands Inc.</a></p>
<p>View source version on accesswire.com: <br/><a href="https://www.accesswire.com/634199/Thoughtful-Brands-Merger-with-Franchise-Cannabis-Terminated" rel="noopener noreferrer" target="_blank">https://www.accesswire.com/634199/Thoughtful-Brands-Merger-with-Franchise-Cannabis-Terminated</a></p>
<p><img class="lazy" data-src="https://www.accesswire.com/img.ashx?id=634199" data-srcset="" height="0" src="https://www.accesswire.com/img.ashx?id=634199" srcset="" width="0"/></p></div>
<p>News Provided by ACCESSWIRE via QuoteMedia</p>
<p></p>
Keep reading...
Show less
Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.
<p>At a critical point for the sector, <span>Monica Chadha, national cannabis leader for EY Canada, spoke about the state of M&A in the Canadian cannabis landscape and about </span>the framework needed for this activity.</p>
<p><span>Chadha shared with the Investing News Network her perspective on the factors that come into play whenever M&A enters the picture, and discussed the particularities involved in cannabis M&A.</span></p>
<div class="cp-text-ad"><div class="row text-ad-ofie">
<div class="ad-image large-4 medium-4 small-12 columns"><a href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing">
<img alt="Cannabis Free Report Cover" class="hide-for-small-only" src="https://cdn.investingnews.com/app/uploads/2020/05/Profiting-from-Cannabis-Industry-3D.jpg" title="Profiting from the Cannabis Industry"/></a></div>
<div class="ad-copy large-8 medium-8 small-11 columns"><a href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing">
<h2 align="center" class="ofie">Find out what experts say about profiting from the cannabis market in 2021!</h2></a>
<h5 align="center" class="subheadline">Read our FREE 2021 cannabis outlook report!</h5>
<div align="center"><a class="button red radius" href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing"> Give me my free report! </a></div>
</div>
<!-- end large-8 -->
</div></div>
<p>“I think the flavor of the year, and maybe next year, will be consolidation, and I think companies that are not fortunate enough to raise or strategically deploy capital will likely see more closures,” Chadha said.</p>
<p>The Canadian cannabis marketplace has recently seen some critical acquisition deals, which may hint at the consolidation trend outlined by the expert.</p>
<p>As it stands, Canadian operators are <a href="https://investingnews.com/daily/cannabis-investing/us-focus-could-drive-ma-canadian-cannabis-operators/" rel="noopener noreferrer" target="_blank">increasingly interested</a> in the possibilities associated with the US cannabis market. One way these firms may gain access to the market below the border is through M&A.</p>
<p>As the leader of the cannabis team at EY Canada, Chadha works with businesses on their strategy, including evaluating the key initial aspects of what would make sense in terms of a partnership.</p>
<p>“Really evaluating some of the softer aspects of cultural fit, strategic direction, market presence are some of the factors we’d consider in conjunction with obviously financial,” Chadha said.</p>
<p>Check out the video above to hear the full conversation with Chadha and her insights on cannabis M&A.</p>
<p><i>Don’t forget to follow us</i><i> <em><a href="https://twitter.com/inn_cannabis" rel="noopener noreferrer" target="_blank">@INN_Cannabis</a> </em>for real-time news updates!</i></p>
<p><b>Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.</b></p>
<p><strong>Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.</strong></p>
<div class="cp-text-ad"><div class="row text-ad-ofie">
<div class="ad-image large-4 medium-4 small-12 columns"><a href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing">
<img alt="Cannabis Free Report Cover" class="hide-for-small-only" src="https://cdn.investingnews.com/app/uploads/2020/05/Profiting-from-Cannabis-Industry-3D.jpg" title="Profiting from the Cannabis Industry"/></a></div>
<div class="ad-copy large-8 medium-8 small-11 columns"><a href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing">
<h2 align="center" class="ofie">Find out what experts say about profiting from the cannabis market in 2021!</h2></a>
<h5 align="center" class="subheadline">Read our FREE 2021 cannabis outlook report!</h5>
<div align="center"><a class="button red radius" href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing"> Give me my free report! </a></div>
</div>
<!-- end large-8 -->
</div></div>
Keep reading...
Show less
Lobe Sciences Completes Previously Announced Sale of Cannabis Assets to Ionic Brands
March 08 | 2021
Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).
<p>Philip Young, CEO and Director of Lobe stated, “This sale provides us with substantial non-dilutive capital to grow our business and accelerate our research and device development. Ionic Brands has been expanding their footprint in the US cannabis market, and this sale allows Lobe to continue to be invested in this exciting sector. The Company continues to focus on its psychedelics business segment, and plans to provide an update on its pre-clinical studies with the University of Miami in the near future. The Company intends to capitalize on the growing mental health sector including the use of other psychedelics with and without NAC using our proprietary nasal delivery device.”</p>
<p><b>Transaction Highlights:</b></p>
<ul class="ee-ul"><li>Strengthens Lobe’s balance sheet with $1.75 million cash on closing</li>
<li>Provides equity ownership in Ionic Brands through the issuance of class E non-voting preferred shares which carry a two-year 13% annual, cumulative, preferential dividend on the issue price per share of $0.30, and which are convertible into common shares of Ionic Brands on a one-for-one basis, as well as additional equity upside through warrants to purchase up to 4,000,000 common shares (subject to Lobe’s covenant not to convert if conversion would result in Lobe becoming an insider of Ionic Brands based on post-conversion beneficial ownership)</li>
<li>Commitment from Ionic Brands to significantly improve its balance sheet through the conversion of outstanding Debentures</li>
<li>Lobe’s subsidiary vendor issued a US$50,000 promissory note from Ionic Brands bearing interest at 7% and maturing in two years, secured against the purchased assets</li>
<li>Allows Lobe to continue to be exposed to the cannabis sector and the broader mental health and wellness industry utilizing transformative medicine, while permitting Lobe to focus on its core business relating to R&D of psychedelic medicines</li>
<li>Provides Lobe with certain minority board representation rights with respect to the board of directors of Ionic Brands</li>
</ul><p>Further to the Company’s press release dated February 23, 2021, in connection with the closing of the Transaction, the Company amended the terms of the asset purchase agreement governing the Transaction. In particular, and following Ionic Brand’s news release on March 2, 2021 confirming that it had closed a $14.7 million oversubscribed private placement and had entered into debenture conversion and voting support agreement with holders of 80.2% of the outstanding principal amount of secured convertible debentures (the “<b>Ionic Debentures</b>“), Ionic Brands covenanted in favour of Lobe’s vendor subsidiary to convert, within 60 days following the date hereof, at least 90% of the principal amount of the outstanding Ionic Debentures, resulting in obligations outstanding (including principal and accrued interest, if any) of no more than $1,800,000 as at the date of conversion. Furthermore, Ionic Brands has agreed to certain minority board nomination rights in favour of Lobe.</p>
<p>For further details regarding the Transaction, please refer to the news release of the Company dated February 23, 2021 and the asset purchase agreement dated February 22, 2021 between the Company’s subsidiary vendor and Ionic Brands in respect of the Transaction, copies of which are filed under Lobe’s SEDAR profile at <a href="https://www.newsfilecorp.com/redirect/vvMWsexbg" rel="noopener noreferrer" target="_blank">www.sedar.com</a>.</p>
<p><b>About <a href="https://investingnews.com/company-profiles/lobe-sciences-cse-lobe/">Lobe Sciences Ltd.</a> </b></p>
<p><a href="https://investingnews.com/company-profiles/lobe-sciences-cse-lobe/">Lobe Sciences</a> is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.</p>
<p><b>For further information please contact: </b><br/><b><a href="https://investingnews.com/company-profiles/lobe-sciences-cse-lobe/">Lobe Sciences Ltd.</a> </b><br/>Philip J. Young, CEO <br/><a href="mailto:info@lobesciences.com" rel="noopener noreferrer" target="_blank">info@lobesciences.com </a><br/>Tel: (949) 505-5623 </p>
<p><i>THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.</i></p>
<p><i><b>Disclaimer for Forward Looking Statements </b></i></p>
<p><i>This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, the Transaction and terms with Ionic and estimated value to Lobe, the benefits of the Transaction, including the benefits of non-dilutive capital and shareholder value to Lobe, the pursuit of other M&A initiatives, continued research and results of pre-clinical studies with the University of Miami, development of effective delivery methods and commercialization potential of the nasal mist device, research and development using NAC and psilocybin and growth of the business, are forward looking statements that are based on assumptions considered to be reasonable by management of the Company at the time such statements are made, and which involve known and unknown risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; counterparty credit risk, risks relating to ownership of securities of Ionic Brands, and the risks relating to the business of Ionic Brands and that the current board of directors of Lobe and its management may not be able to attain the Company’s corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.</i></p>
<p id="corporateNewsLogoContainer"><img alt="Corporate Logo" class="lazy" data-src="https://orders.newsfilecorp.com/files/6461/76393_839c6eff049989e5_logo.jpg" data-srcset="" id="corporateNewsLogo" src="https://orders.newsfilecorp.com/files/6461/76393_839c6eff049989e5_logo.jpg" srcset=""/></p>
<p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://www.newsfilecorp.com/redirect/JrB0CEQBv" rel="noopener noreferrer" target="_blank">https://www.newsfilecorp.com/release/76393</a></p>
<p><img alt="" class="lazy" data-src="https://www.newsfilecorp.com/newsinfo/76393/310" data-srcset="" src="https://www.newsfilecorp.com/newsinfo/76393/310" srcset=""/></p>
</div>
<p>News Provided by Newsfile via QuoteMedia</p>
<p></p><div class="stock-information sidebar-block">
<div class="title">Request an Investor Kit: <h3>Lobe Sciences</h3></div>
<form action="https://investingnews.com" id="subscribe_per_category" method="POST">
<div class="form-column left">
<input name="profiles_only" type="hidden" value="yes"/><input name="subscription_form" type="hidden" value="yes"/><input name="subscribe_company_profile_form" type="hidden" value="1"/><input name="source" type="hidden" value="https://investingnews.com/news/cannabis-investing/lobe-sciences-completes-previously-announced-sale-of-cannabis-assets-to-ionic-brands/"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="form_name" type="hidden" value="subscribe_cprofile_use_posts"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="cprofiles[]" type="hidden" value="Tzo4OiJzdGRDbGFzcyI6NDp7czoyOiJpZCI7czozNjoiODY3MWZiY2MtYjE5MS01ZmQ2LWM0ODktNWZiMmE5NTNmZjcxIjtzOjQ6Im5hbWUiO3M6MTM6IkxvYmUgU2NpZW5jZXMiO3M6NDoid3BpZCI7czo5OiIxMDE1OTE5NjUiO3M6MzoidXJsIjtzOjA6IiI7fQ=="/><input class="form-control" id="FirstName" name="first_name" placeholder="First Name" required="" type="text" value=""/><input class="form-control" id="LastName" name="last_name" placeholder="Last Name" required="" type="text" value=""/><input class="form-control" id="email" name="email" placeholder="Email" required="" type="email" value=""/><input class="form-control" id="phone" name="user_phone" pattern="[\+\s0-9]{3,15}" placeholder="Phone" title="Telephone number. Only digits and space signs are allowed" type="tel" value=""/></div>
<div class="form-column right">
<div class="extra-input">
<input id="AccreditedInvestor" name="accredited_investor" type="checkbox"/><label class="checkbox-label" for="AccreditedInvestor">
Include me in the <b>Accredited Investor</b> email list
<span class="help">
<i aria-hidden="true" class="fa fa-question-circle"></i>
<div class="help-box bigger">
Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for "accredited investor" in the search bar above.
</div>
</span>
</label>
</div>
<div class="more">
<input class="btn btn-primary" type="submit" value="Get More information"/></div>
<p class="legend">By completing this form, you are giving consent to receive communication from Lobe Sciences using the contact information you provide. And remember you can unsubscribe at any time.</p>
</div>
</form>
</div>
Keep reading...
Show less
Seattle Area Grocery Chain Metropolitan Market to Begin Carrying KOIOS and Fit Soda on March 22, 2021
March 08 | 2021
Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.
<p>Metropolitan Market was founded in 1971 as an independent grocer defined by its “curious” approach to merchandising, which made it the first to carry certain products in the Seattle area such as <em> Copper River </em> salmon. With a total of eight stores in Kirkland, Magnolia, Mercer Island, Queen Anne, Sand Point, Sammamish, Tacoma, and West Seattle, Metropolitan Market has a substantial presence in the Seattle metro area (population 3.87 million as of 2018 <sup> 2 </sup> ). Metropolitan Market’s parent firm <em> Good Food Holdings </em> holds four other west coast grocery banners with a combined total of 51 stores in California, Oregon, and Washington State to include <em> Lazy Acres </em> , <em> Bristol Farms </em> , <em> New Seasons Market </em> , and <em> New Leaf Community Market </em> <sup> 3 </sup> .</p>
<p>More information about Metropolitan Market can be found on its website: <u> <a href="https://metropolitan-market.com/" rel="nofollow noopener noreferrer" target="_blank"> https://metropolitan-market.com/ </a> </u></p>
<p>A photo accompanying this announcement is available at <a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3a60712e-531e-42aa-aedd-2f8e1d6bde5a" rel="nofollow noopener noreferrer" target="_blank"> https://www.globenewswire.com/NewsRoom/AttachmentNg/3a60712e-531e-42aa-aedd-2f8e1d6bde5a </a></p>
<p align="center"><strong> Readers using news aggregation services may be unable to view the media above. Please access the Company’s profile on SEDAR for a version of this press release containing all published media. </strong></p>
<p>On Monday, March 22, 2021, Metropolitan Market will start carrying all five flavours of the <em> KOIOS </em> ™ nootropic beverage ( <em> Black Raspberry </em> , <em> Blood Orange </em> , <em> Peach Mango </em> , <em> Apricot Vanilla </em> , and <em> Pear Guava </em> ) as well as all four flavours of the <em> Fit Soda </em> ™ functional beverage ( <em> Orange Cream </em> , <em> Root Beer Vanilla Float </em> , <em> Black Cherry Cola </em> , and <em> Sparkling Citrus </em> ). The Company believes that as it continues to build its footprint in regional grocers for the Pacific Northwest and Gulf Coast regions of the United States, these targeted efforts could complement other sales channels to include national retail chains such as Walmart as well as e-commerce platforms such as Walmart’s U.S. online store, Amazon.com, and Koios’ direct-to-consumer portal.</p>
<p>Koios Chief Executive Officer Chris Miller commented, “We have long maintained that local grocery chains are exceptionally savvy when it comes to building a loyal client base because they can gather and act upon qualitative insights far more efficiently than a large-scale chain. No matter how advanced a <em> ‘Big Data’ </em> analytics engine may be in anticipating or influencing shopping patterns, the very best insights about what customers actually want comes from the personal relationships you can build with your clientele as a regional operator. This is the backbone of our strategy to gain concentrated market penetration in strategic areas of the United States, as our objective is to cultivate long-term adoption of our beverages as a lifestyle staple and potentially leverage our presence in local chains to qualify for placements in additional national chains. We look forward to building out our presence in the Pacific Northwest as we continue our push to become a more prominent brand in the beverages industry.”</p>
<p><u> Sources </u></p>
<p>1 – <a href="https://www.sprouts.com/stores/" rel="nofollow noopener noreferrer" target="_blank"> <u> https://www.sprouts.com/stores/ </u> </a></p>
<p>2 – <a href="https://www.seattletimes.com/seattle-news/data/seattle-just-one-of-5-big-metros-last-year-that-had-more-people-move-here-than-leave-census-data-show/" rel="nofollow noopener noreferrer" target="_blank"> <u> https://www.seattletimes.com/seattle-news/data/seattle-just-one-of-5-big-metros-last-year-that-had-more-people-move-here-than-leave-census-data-show/ </u> </a></p>
<p>3 – <a href="http://goodfoodholdings.com/" rel="nofollow noopener noreferrer" target="_blank"> <u> http://goodfoodholdings.com/ </u> </a></p>
<p>On behalf of the Board of Directors of the Company,</p>
<p><strong> KOIOS BEVERAGE CORP. </strong></p>
<p>“Chris Miller”</p>
<p>Chris Miller, CEO, and Director</p>
<p>For further information, please contact:</p>
<p>Gina Burrus<br/>
844-255-6467<br/><a href="mailto:gina@koiosbeveragecorp.com" rel="nofollow noopener noreferrer" target="_blank"> <u> gina@koiosbeveragecorp.com </u> </a></p>
<p>THE CANADIAN SECURITIES EXCHANGE (CSE) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.</p>
<p><strong> About Koios Beverage Corp. </strong></p>
<p>The Company is an emerging functional beverage company which has an available distribution network of more than 4,400 retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well. Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants. Koios products have been shown to enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity. Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.</p>
<p>Koios produces one of the only drinks in the world infused with MCT oil. MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: <a href="https://www.koiosbeveragecorp.com" rel="nofollow noopener noreferrer" target="_blank"> <u> https://www.koiosbeveragecorp.com </u> </a> .</p>
<p><strong> Forward-Looking Statements </strong></p>
<p>This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information in this news release includes statements regarding: Potential outcomes from the scheduled placement of <em> KOIOS </em> ™ and <em> Fit Soda </em> ™ beverages in Metropolitan Market stores in Washington State, overall performance of the functional beverage market The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the functional beverage markets; and (iii) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.</p>
<p>The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.</p>
<p>This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by Koios with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with Koios is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.</p>
<p><img class="lazy" data-src="https://www.globenewswire.com/newsroom/ti?nf=ODE4NTg4NyM0MDUyNjA1IzIwOTAwMjM=" data-srcset="" height="1" src="https://www.globenewswire.com/newsroom/ti?nf=ODE4NTg4NyM0MDUyNjA1IzIwOTAwMjM=" srcset="" width="1"/><br/><img class="lazy" data-src="https://ml.globenewswire.com/release/track/65494f6f-c35b-4c5d-a6ca-75a4ed9fc20d" data-srcset="" height="1" src="https://ml.globenewswire.com/release/track/65494f6f-c35b-4c5d-a6ca-75a4ed9fc20d" srcset="" width="1"/></p>
<p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/69225798-53e0-46a5-b563-b49071c3918c" rel="noopener noreferrer" target="_blank"> <img alt="Primary Logo" border="0" class="lazy" data-src="https://ml.globenewswire.com/media/69225798-53e0-46a5-b563-b49071c3918c/small/koios-logo-1-jpg.jpg" data-srcset="" height="150" src="https://ml.globenewswire.com/media/69225798-53e0-46a5-b563-b49071c3918c/small/koios-logo-1-jpg.jpg" srcset="" width="150"/></a></p>
</div>
<p>News Provided by GlobeNewswire via QuoteMedia</p>
Keep reading...
Show less